A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.
The findings were published today in Nature Immunology and validated in both mouse models and humans.
“We think we have uncovered a potential biomarker that signals a patient is experiencing so-called ‘compartmentalized inflammation’ in the central nervous system, a phenomenon which is strongly linked to MS progression,” says Jen Gommerman, a professor and chair of immunology at U of T’s Temerty Faculty of Medicine. “It’s been really hard to know who is progressing and who isn’t.”








